Shares of Ascendis Pharma A/S (NASDAQ:ASND) advanced to $14.24. The price had gained 4.78% or 0.65 points intraday. The latest trading session witnessed $0.29 million in upticks and $8.55 million in downticks, resulting in net money flow of (-8.27) million. The up/down ratio for the day stood at 0.03. On a weekly scale, the price has seen a change of 5.79%. From the trading data available, it was disclosed that a block trade of negative money flow worth $(-8.24) million occurred during the day. $0 million in uptick and $8.24 million in downtick were the highlight of the block transaction which had an up/down ratio of 0.
Shares of Ascendis Pharma A/S appreciated by 3.79% during the last five trading days but lost 1.27% on a 4-week basis. Ascendis Pharma A/S has dropped 20.89% during the last 3-month period . Year-to-Date the stock performance stands at -23.74%.
Institutional Investors own 50.51% of Ascendis Pharma A/S shares. .
Ascendis Pharma A/S (NASDAQ:ASND) rose 2.8% or 0.38 points on Friday and made its way into the gainers of the day. After trading began at $13.69 the stock was seen hitting $14.535 as a peak level and $13.6 as the lowest level. The stock ended up at $13.97. The daily volume was measured at 730,977 shares. The 52-week high of the share price is $23.81 and the 52-week low is $11.92. The company has a market cap of $351 million.
Ascendis Pharma A/S is a clinical stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its lead product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Insulin for the treatment of diabetes, TransCon Peptide for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology.